Kitty Yale

KITTY YALE is vice president of clinical operations with Gilead Sciences, Inc. She joined Gilead in November 2001 and was appointed to her current position in 2016. In this role, she is responsible for oncology, liver disease, inflammation, global and early development (Phase 1) clinical operations teams. At Gilead, she has been involved in the successful development and approval process for eight infectious disease drug products leading the clinical operations team. Yale has over 20 years of drug development experience in the biotechnology and pharmaceutical industries. Prior to joining Gilead she held roles management roles at Pfizer, Innovex (Quintile’s) and Roche. She earned a B.Sc. in applied biology from Glasgow Caledonian University and a B.Sc. in molecular genetic from Glasgow Caledonian University , Scotland. @gileadsciences